Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genmab | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 88.90B | 19.1x | 1.34 | DKK 1,402.50 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 52.03B | -44.7x | 3.01 | DKK 736.50 | 7.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.5% Upside | Upgrade to Pro+ | |
Gubra AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 9.92B | -249.6x | 0.56 | DKK 604 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ViroGates | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 86.63M | -5.8x | -0.2 | DKK 11.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Strategic Partners AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 34.99M | -2.6x | -0.04 | DKK 838.80 | 6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |